Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Feasibility of Outpatient High Dose Cytarabine in Patients with Acute Myeloid Leukemia

Chin-Hin NG, MD MRCP, FRCPATH, MCI, Xiaojuan Chen, BsN, MsN, Foong-Gwan Lee, BsN, Shi Hui Clarice Choong, MBBS, MRCP, Xiao-Shi Saw, BSc(Pharm), Lon-Wann Sai, MBBS, MRCP, Michelle Poon, MBBS, MRCP, FRCPATH, Hian Li Esther Hian Li Chan, MBBS, MRCP, FRCPATH, Melissa Ooi, MB BCh, BAO, MRCP(I), FRCPath, PhD, Yen Lin Chee, MBBS, FRCPATH, PhD, Yee Mei Lee, BsN, MsN, PhD

Blood (2019) 134 (Supplement_1): 2152.

https://doi.org/10.1182/blood-2019-129858

Published: 2019

Journal Articles

Whole Exome Sequencing of Relapsed Double-Mutated CEBPA Acute Myeloid Leukemia Identified Mutated KIT and WNT10A As a Potential Co-Mutation with Negative Impact on Prognosis

Chin-Hin NG, MD MRCP, FRCPATH, MCI, Alvin Yu-Jin Ng, PhD, Benedict Yan, MBBS, Wee-Joo Chng, MBBS, PhD

Blood (2019) 134 (Supplement_1): 5177.

https://doi.org/10.1182/blood-2019-127727

Published: 2019

Journal Articles

Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity

Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Chin Hin Ng, MD MRCP, Ashish Bajel, MBBS, FRACP, FRCPA, William YK Hwang, MBBS, FRCP(London), MMed(Int MD, FAMS, Shir-Jing Ho, MBBS, FRACP, FRCPA, MClinTrial Res, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Mark McHale, B.S., PhD, Chih-Yi Hsieh, MD, Hsuan-Jen Shih, MD, Nicola McIntyre, PhD, Jamie Kwek, Wei-Ling Chang, PhD, Bertil Lindmark, MD PhD

Blood (2018) 132 (Supplement 1): 2676.

https://doi.org/10.1182/blood-2018-99-110570

Published: 2018

Journal Articles

Single Institution Phase 1 Study on Combination Therapy of Midostaurin and Panobinostat in Acute Myeloid Leukemia - the Interim Report

Chin-Hin NG, MD MRCP, FRPATH, Liang Piu Koh, MBBS, MRCP, Melissa Ooi, MB BCh, BAO, MRCP(I), FRCPath, PhD, Wei Ying Jen, MA, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS

Blood (2018) 132 (Supplement 1): 5237.

https://doi.org/10.1182/blood-2018-99-120327

Published: 2018

Journal Articles

Plasma LRG1 Protein Are Overexpressed in Acute Myeloid Leukemia with High Sensitivity and High Specificity in Differentiating Leukemic Plasma from Normal Plasma — a Potential Biomarker for Minimal Residual Disease Detection

Chin Hin Ng, MD MRCP, Xu Liang, PhD, Jianbiao Zhou, MD PhD, Elaine Seah, BSc, Baohong Lin, BSc, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Yoon-Pin Lim, BSc, PhD

Blood (2017) 130 (Supplement 1): 5083.

https://doi.org/10.1182/blood.V130.Suppl_1.5083.5083

Published: 2017

Journal Articles

Pediatric-Inspired Protocol Improved Overall Survival in Young Adult Aged 18-30 Years Old with Philadelphia-Negative Acute Lymphoblastic Leukemia Compared to the Standard Adult Hypercvad Protocol

Victor Ling Wei Teik, MD MRCP, Elaine Seah, BSc, Michelle Poon, Melissa Ooi, Allen Eng Juh Yeoh, MD, Chin Hin Ng, MD MRCP

Blood (2017) 130 (Supplement 1): 5043.

https://doi.org/10.1182/blood.V130.Suppl_1.5043.5043

Published: 2017

Journal Articles

MAPKAP1 (Sin1), a Key Component of the MTORC2 Complex, Confers Resistance to Sorafenib and Correlates with Adverse Clinical Outcomes in Acute Myeloid Leukemia

Joseph David Khoury, MD, Ioanna Xagoraris, MD, Nikolaos Tsesmetzis, MSc., Ida Hed Hed Myrberg, PhD, Thale Kristin Olsen, Siok Bian Ng, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Benedict Yan, Chin Hin Ng, MD MRCP, Michael Andreeff, MD PhD, L. Jeffrey Medeiros, MD, Hagop M. Kantarjian, MD, Herold Nikolas, MD PhD, Dan Grander, MD PhD, George Rassidakis, MD PhD

Blood (2017) 130 (Supplement 1): 3964.

https://doi.org/10.1182/blood.V130.Suppl_1.3964.3964

Published: 2017

Journal Articles

Plasma HCK Level As a Biomarker Predicting Poor Outcome in Acute Myeloid Leukemia

Pak Ling Lui, MBBS, Elaine Seah, BSc, Jianbiao Zhou, MD PhD, Baohong Lin, BSc, Wee Joo Chng, MB ChB, MRCP, PhD, Chin Hin Ng, MD MRCP

Blood (2017) 130 (Supplement 1): 3862.

https://doi.org/10.1182/blood.V130.Suppl_1.3862.3862

Published: 2017

Journal Articles

Presence of Post Induction Minimal Residual Disease (MRD) Is an Independent Predictor for Relapse and Is Associated with Inferior Survival in Acute Myeloid Leukemia (AML)

Winnie ZY Teo, MRCP, MBBS, Elaine Seah, BSc, Shir Ying Lee, FRCPath,MBBS,MRCP,, Te-Chih Liu, FRCPath, MBBS, MRCP, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Chin Hin Ng, MD MRCP

Blood (2017) 130 (Supplement 1): 1389.

https://doi.org/10.1182/blood.V130.Suppl_1.1389.1389

Published: 2017

Journal Articles

Clinical Outcomes of Phase I/II Clinical Trials for Patients with Relapsed/Refractory Haematological Malignancies: Experience of an Early Phase Clinical Trials Unit

Chin-Hin Ng, MD MRCP, FRCPATH, Dima El-Sharkawi, MD, Elspeth M Payne, MDPhD, Kwee L Yong, Kirit M Ardeshna, MD FRCP, FRCPATH, Asim Khwaja, FRCPath, Rakesh Popat

Blood (2016) 128 (22): 3613.

https://doi.org/10.1182/blood.V128.22.3613.3613

Published: 2016

Journal Articles

A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial

Rakesh Popat, Sarah R Brown, Avie-Lee Tillotson, Fiona Collinson, Louise M Flanagan, Cathy D Williams, Kwee L Yong, Gordon Cook, MD PhD, Matthew W Jenner, MD, Martin Kaiser, Jim Cavet, FRCPath, Dima El-Sharkawi, MD, Chin-Hin Ng, MD MRCP, FRCPATH, Eric Low, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2016) 128 (22): 3321.

https://doi.org/10.1182/blood.V128.22.3321.3321

Published: 2016

Journal Articles

Paediatric-Inspired Acute Lymphoblastic Leukemia Protocols, Are They Too Toxic for Young Adults?

Melissa G. Ooi, MDMRCP FRCPath PhD, Wee J Chng, MD MRCP, FRCPATH, PhD, Chin-Hin Ng, MD MRCP, FRCPATH, Yi Ching Yuen, MClinPharm, BCOP, BCPS, CGP, Allen Eng Juh Yeoh, MD, Chiew Kean Hui, Elaine Seah, BSc

Blood (2016) 128 (22): 5162.

https://doi.org/10.1182/blood.V128.22.5162.5162

Published: 2016

Journal Articles

A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma

Graham P. Collins, MD PhD, Rakesh Popat, Anastasios Stathis, Fatime Krasniqi, MD PhD, Toby A. Eyre, MD, Chin Hin Ng, MD, Dima El-Sharkawi, MD, Christian Schmidt, MD, Andreas Wicki, MDPhD, Elena Ivanova, PhD, Debora Schmitz, PhD, Sasa Dimitrijevic, PhD, Martin H. Dreyling, MD PhD

Blood (2016) 128 (22): 5893.

https://doi.org/10.1182/blood.V128.22.5893.5893

Published: 2016

Journal Articles

Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Blood (2016) 128 (22): 624.

https://doi.org/10.1182/blood.V128.22.624.624

Published: 2016

Journal Articles

The Plasma Level of Leukemia Stem Cell Specific Antigens - CLL1 and TIM3 Are Predictive of Overall Survival in Acute Myeloid Leukemia

Chin-Hin Ng, MD MRCP, FRCPATH, Ma Thin Mar Win, MBBS, MPH, MHM, Elaine Seah, BSc, Wee-Joo J Chng, MD MRCP, FRCPATH, PhD

Blood (2015) 126 (23): 1407.

https://doi.org/10.1182/blood.V126.23.1407.1407

Published: 2015

Journal Articles

Characterization of AML Patients with CEBPA Mutations in a South-East Asian Population

Peak-Ling Lee, Benedict Yan, MBBS, FRCPath, Chin-Hin Ng, MD MRCP, FRCPATH, Kenneth Hon-Kim Ban, MD PhD, Wee-Joo Chng, MBBS, MRCP, FRCPath, PhD, Evelyn Siew-Chuan Koay, FRCPath,PhD

Blood (2015) 126 (23): 2574.

https://doi.org/10.1182/blood.V126.23.2574.2574

Published: 2015

Journal Articles

Incidence and Clinical Features of Calreticulin mutation in Patients with Jak2 V617F-Negative Essential Thrombocytosis and Primary Myelofibrosis from Singapore

Chin-Hin Ng, MD MRCP, FRCPath, Christopher W.S Ng, BSc, Bingwen Eugene Fan, MBBS, MRCP, Kiat-Hoe Ong, MBBS, MRCP, FRCPA, Elaine Seah, BSc, Huijun Zhou, MBBS, MSc, PhD, Siew-Chuan Evelyn Koay, FRCPath,PhDBSc,MSc, Wee-Joo Chng, MBBS, MRCP, FRCPath, PhD

Blood (2014) 124 (21): 3176.

https://doi.org/10.1182/blood.V124.21.3176.3176

Published: 2014

NARROW

Feasibility of Outpatient High Dose Cytarabine in Patients with Acute Myeloid Leukemia

Whole Exome Sequencing of Relapsed Double-Mutated CEBPA Acute Myeloid Leukemia Identified Mutated KIT and WNT10A As a Potential Co-Mutation with Negative Impact on Prognosis

Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity

Single Institution Phase 1 Study on Combination Therapy of Midostaurin and Panobinostat in Acute Myeloid Leukemia - the Interim Report

Plasma LRG1 Protein Are Overexpressed in Acute Myeloid Leukemia with High Sensitivity and High Specificity in Differentiating Leukemic Plasma from Normal Plasma — a Potential Biomarker for Minimal Residual Disease Detection

Pediatric-Inspired Protocol Improved Overall Survival in Young Adult Aged 18-30 Years Old with Philadelphia-Negative Acute Lymphoblastic Leukemia Compared to the Standard Adult Hypercvad Protocol

MAPKAP1 (Sin1), a Key Component of the MTORC2 Complex, Confers Resistance to Sorafenib and Correlates with Adverse Clinical Outcomes in Acute Myeloid Leukemia

Plasma HCK Level As a Biomarker Predicting Poor Outcome in Acute Myeloid Leukemia

Presence of Post Induction Minimal Residual Disease (MRD) Is an Independent Predictor for Relapse and Is Associated with Inferior Survival in Acute Myeloid Leukemia (AML)

Clinical Outcomes of Phase I/II Clinical Trials for Patients with Relapsed/Refractory Haematological Malignancies: Experience of an Early Phase Clinical Trials Unit

A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial

Paediatric-Inspired Acute Lymphoblastic Leukemia Protocols, Are They Too Toxic for Young Adults?

A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma

Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

The Plasma Level of Leukemia Stem Cell Specific Antigens - CLL1 and TIM3 Are Predictive of Overall Survival in Acute Myeloid Leukemia

Characterization of AML Patients with CEBPA Mutations in a South-East Asian Population

Incidence and Clinical Features of Calreticulin mutation in Patients with Jak2 V617F-Negative Essential Thrombocytosis and Primary Myelofibrosis from Singapore

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only